Mortality and clinical outcomes in preterm infants with patent ductus arteriosus according to pharmacological treatment or expectant management: a retrospective cohort study.
4 affiliations
- 1INSIDE Group Research, School of Medicine, Faculty of Health, Universidad del Valle, Cali, Colombia.
- 2Department of Pediatrics, School of Medicine, Faculty of Health, Universidad del Valle, Cali, Colombia.
- 3Versailles Clinic Cali, Cali, Colombia.
- 4Faculty of Health Sciences, Universidad ICESI, Cali, Colombia.
Abstract
Introduction
Patent ductus arteriosus (PDA) is frequent in preterm newborns and its management remains controversial. The objective was to evaluate the association between pharmacological treatment of PDA and mortality in preterm infants.Methods
Retrospective cohort study. A sample size of 154 patients was estimated. Comparisons were performed using the Chi-square test for qualitative variables, and the Mann-Whitney test for continuous variables. Survival analysis was performed using the Kaplan-Meier curve and log-rank test. Cox regression models were used to estimate Hazard ratios (HR) with 95% confidence intervals (95% CI).Results
A total of 156 patients were included. In the survival analysis, Kaplan-Meier curves showed a lower probability of survival in the treated group.In the Cox proportional hazards model, pharmacological treatment was not independently associated with mortality (HR: 2.25; 95% CI: 0.86-5.88; p = 0.09). Birth weight was independently associated with a lower mortality hazard rate (HR: 0.997; 95% CI: 0.995-0.999; p = 0.020). No significant associations were observed with sepsis.Conclusion
Expectant management was not associated with an increase in morbidity or mortality. The lower survival observed with pharmacological treatment in the unadjusted analyses was not maintained after adjustment.
Related
- Association between early intravenous magnesium sulfate administration and mortality according to systemic immune-inflammation index in critically ill patients with acute heart failure: A retrospective cohort study.
- A Single-Center Retrospective Analysis of the Diagnostic Efficacy of Transthoracic Echocardiography in the Classification of Patent Ductus Arteriosus
- Comparison of indomethacin and nifedipine regarding ductus arteriosus Doppler findings after laser therapy for monochorionic diamniotic twin-to-twin transfusion syndrome: A retrospective cohort study
- Evolution of treatment strategies and risk-stratified management of patent ductus arteriosus in preterm infants
- Home-based non-pharmacological interventions for cognition and diabetes self-management in adults with type 2 diabetes: a systematic review
BibTeX
@article{torresmunoz2026mortality,
title = {{Mortality and clinical outcomes in preterm infants with patent ductus arteriosus according to pharmacological treatment or expectant management: a retrospective cohort study.}},
author = {Javier Torres-Muñoz and Diana María Pérez Manrique and Lesly Georjany Escobar Gordillo and Angie Marcela Guapacha Alomia and Julián Torres-Figueroa},
journal = {Frontiers in pediatrics},
year = {2026},
month = oct,
doi = {10.3389/fped.2026.1952588},
url = {https://europepmc.org/article/MED/42923308},
note = {CC BY},
}
RIS
TY - JOUR
TI - Mortality and clinical outcomes in preterm infants with patent ductus arteriosus according to pharmacological treatment or expectant management: a retrospective cohort study.
AU - Javier Torres-Muñoz
AU - Diana María Pérez Manrique
AU - Lesly Georjany Escobar Gordillo
AU - Angie Marcela Guapacha Alomia
AU - Julián Torres-Figueroa
PY - 2026
DA - 2026/10/08
JO - Frontiers in pediatrics
DO - 10.3389/fped.2026.1952588
UR - https://europepmc.org/article/MED/42923308
AB - Introduction Patent ductus arteriosus (PDA) is frequent in preterm newborns and its management remains controversial. The objective was to evaluate the association between pharmacological treatment of PDA and mortality in preterm infants.Methods Retrospective cohort study. A sample size of 154 patients was estimated. Comparisons were performed using the Chi-square test for qualitative variables, and the Mann-Whitney test for continuous variables. Survival analysis was performed using the Kaplan-Meier curve and log-rank test. Cox regression models were used to estimate Hazard ratios (HR) with 95% confidence intervals (95% CI).Results A total of 156 patients were included. In the survival analysis, Kaplan-Meier curves showed a lower probability of survival in the treated group.In the Cox proportional hazards model, pharmacological treatment was not independently associated with mortality (HR: 2.25; 95% CI: 0.86-5.88; p = 0.09). Birth weight was independently associated with a lower mortality hazard rate (HR: 0.997; 95% CI: 0.995-0.999; p = 0.020). No significant associations were observed with sepsis.Conclusion Expectant management was not associated with an increase in morbidity or mortality. The lower survival observed with pharmacological treatment in the unadjusted analyses was not maintained after adjustment.
SN - 2296-2360
ER -